Base to Base Biotech

Jim Cornall
  • 0.0 (0)
  • Medicine
  • Weekly

The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.

  1. 2d ago

    Base to Base biotech podcast 82: Restoring blood flow to the heart and tackling HHT

    This week, we have a conversation with Philip Brainin, CEO of Isomab, about restoring blood flow to the heart, and with RougeTx CEO Andrew Lightfoot, about developing a treatment for hereditary haemorrhagic telangiectasia (HHT). Times: 03:34 Isomab 25:29 RougeTx Isomab Isomab, a preclinical UK biotech, recently presented safety data at ESC recently that may not sound particularly exciting at first glance, but the implications for cardiovascular drug development could be significant. For decades, the field has been trying to stimulate new blood vessel growth to restore blood flow to the heart, but concerns that this could increase the risk of cancer or damage to the retina have been a major barrier. Isomab’s systematic review of more than 20 years of clinical trial data found no evidence of these long-held safety concerns, potentially removing a significant obstacle to developing an entirely new class of disease-modifying cardiovascular therapies. Isomab believes its approach could open up a new avenue for treating coronary artery disease. The company has a lead drug candidate in ISM-001, which selectively removes VEGF-A165b to restore the natural signalling balance that enables healthy vascularisation in the heart. VEGF-A165b was first identified in 2001 by David Bates, scientific founder of Isomab, and has since been validated in more than 100 publications from more than 80 independent laboratories worldwide. RougeTx RougeTx, launched recently with a $58m Series A financing to advance first-in-class therapies designed to restore vascular integrity by targeting pericyte dysfunction. RougeTx is developing novel therapies for diseases driven by vascular instability, with lead programme RTX-001 advancing towards first-in-human clinical development for hereditary haemorrhagic telangiectasia (HHT), a serious inherited bleeding disorder for which there are currently no approved therapies. RougeTx's periSCOPE platform is being used to identify additional opportunities across diseases associated with vascular instability. The company is built on more than two decades of research into the role of pericytes in maintaining blood vessel integrity. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 82: Restoring blood flow to the heart and tackling HHT

  2. Oct 23

    Base to Base biotech podcast 81: Breakthrough in shrinking tumours and restoring mitochondrial metabolism to address obesity

    This week, we talk about mitochondria and obesity with Jon Rees, co-founder and CEO of MitoRx Therapeutics, and also have a chat with Apeximmune Therapeutics’ CEO and founder Li-Fen Lee, and senior director of biology Kan Lu, about a new breakthrough in shrinking tumours. Times: 03:11 MitoRx Therapeutics 25:06 Apeximmune Therapeutics MitoRx Therapeutics MitoRx Therapeutics is developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity. Its first-in-class small molecule asset, MTRX31, targets the elimination of ectopic fat in people with metabolically unhealthy obesity, by restoring mitochondrial health rather than suppressing appetite. Preclinical data for MTRX31 has shown superior magnitude, quality and durability of weight loss compared with tirzepatide in an industry-standard preclinical model of obesity. MTRX31-driven weight loss does not involve lean mass loss, meaning basal metabolic rate is maintained – providing durable, healthy weight loss. The company recently presented new preclinical data at the EASD conference recently.. Apeximmune Therapeutics Apeximmune Therapeutics, Inc. is an IND-stage biotechnology company in South San Francisco focused on developing novel immunotherapies for patients who do not respond to existing immune checkpoint inhibitors. The company applies proprietary computational target discovery to identify mechanistically distinct immune checkpoints with the potential to expand the reach of immuno-oncology. The company recently saw its research published in Nature with a piece entitled “PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity.” The publication validated PLA2G2D as a novel and mechanistically distinct immune checkpoint capable of addressing resistance to anti-PD-1 therapy. The publication represents the convergence of two independent research programmes – one led by Apeximmune, the other by researchers at Erasmus University Medical Center in Rotterdam, the Netherlands – that arrived at the same target using different approaches. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 81: Breakthrough in shrinking tumours and restoring mitochondrial metabolism to address obesity

  3. Oct 16

    Base to Base biotech podcast 80: Targeting tumour acidity, and developing allosteric therapies

    This week, we chat with Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, about tumour acidity, and Gene Mack, president and CEO of Gain Therapeutics, about developing allosteric therapies, including taking Parkinson’s disease treatments beyond addressing symptoms. Times: 03:03 Gain Therapeutics 25:48 Dyve Biosciences Gain Therapeutics Gain Therapeutics is developing next-generation allosteric therapies. Its lead drug candidate, rexaceract is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a phase 1b clinical trial. Rexaceract has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Also, it has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumours. Its approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its Magellan platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology. Dyve Biosciences Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, invented a first-of-its-kind therapy that delivers sodium bicarbonate through the skin to target tumour acidity throughout the body. The therapy is designed to address a key limitation of earlier efforts, which relied on delivering large amounts of buffering agents orally. In preclinical research with Moffitt Cancer Center, DYV800 made tumours substantially less acidic, restored T-cell activity, slowed tumour growth and improved survival. The findings were recently published in Frontiers in Immunology, and the next step is bringing the therapy to patients. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 80: Targeting tumour acidity, and developing allosteric therapies

  4. Oct 9

    Base to Base biotech podcast 79: Fragile X syndrome and Parkinson’s disease

    This week, we chat with Simon Mølgaard, co-founder and chief executive officer of Teitur Trophics about results from its Parkinson’s disease trial, and have a conversation with Jordi Fàbrega, co-founder and CEO of CONNECTA Therapeutics, and Josep Prous, co-founder and chief scientific officer, about Fragile X syndrome. Times: 03:15 Teitur Trophics 14:03 CONNECTA Therapeutics Teitur Trophics Teitur Trophics recently announced successful results from its phase I clinical trial of its lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD). The positive results support plans to initiate a phase II trial in PD patients in 2027, which will be designed to explore the therapeutic benefit and disease modifying potential of TT-P34. TT-P34 is a first-in-class therapy that, through a dual mechanism of action, improves both mitochondrial and lysosomal function. Its unique mode of action, targeting a critical pathway that underpins multiple aspects of pathology, means TT-P34 also has potential as a disease-modifying drug for other neurodegenerative conditions including frontotemporal dementia and Huntington’s disease. CONNECTA CONNECTA Therapeutics is a Barcelona-based clinical-stage biotech company developing first-in-class neuroplasticity modulators for central nervous system (CNS) disorders. The company recently announced a €3.1m financing to support the advancement of CTH120, CONNECTA's lead programme for Fragile X syndrome (FXS), including completion of the ongoing phase IIa clinical trial in adult males with FXS, with topline data expected in mid-2027. The financing comes at a key stage for the company as it works to address the underlying neurobiology of FXS, a rare and currently untreatable neurodevelopmental disorder, through its differentiated neuroplasticity modulation platform. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 79: Fragile X syndrome and Parkinson’s disease

  5. Oct 2

    Base to Base biotech podcast 78: A new treatment for erectile dysfunction, and nanotechnology for knee osteoarthritis

    This week, we chat with Lucas Decuypere, CEO and president of Allegro, about treatment of knee osteoarthritis with a nanotechnology injection, and Elin Trampe, the CEO of Dicot Pharma, a company developing a new form of erectile dysfunction treatment. Times: 01:46 Dicot Pharma 17:21 Allegro Allegro Allegro is a Belgium-based biomedical company which recently announced statistically significant improvements in pain and function in a 30-patient study of hydrocelin, a first-in-class nanotechnology injection for knee osteoarthritis (OA). Rather than lubricating the joint like existing injectables such as hyaluronic acid or corticosteroids, hydrocelin uses cross-linked microparticles designed to physically restore the shock-absorbing mechanics of synovial fluid, thereby targeting a proposed root cause of OA rather than just masking symptoms. Separately, Allegro just completed enrolment in a parallel European feasibility trial two months ahead of schedule. Topline safety/tolerability data are expected in H2 2026 and will inform a planned global registrational study. Dicot Pharma Dicot Pharma is developing the first innovation to erectile dysfunction in last 30 years. Virtually nothing has happened since Viagra and Cialis were introduced. The company has recently been given the green light to start its phase IIb trials in the US, and trials are about to start in the EU, too. The drug, LIB-01 has a completely different mode of action, which means a wider group of men can take it. Taking three pills means the drug will work spontaneously for eight weeks, meaning couples do not need to plan anything. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 78: A new treatment for erectile dysfunction, and nanotechnology for knee osteoarthritis

  6. Sep 25

    Base to Base biotech podcast 77: Transferring mammal traits to humans, and is injecting tumours a new way to kill cancer?

    This week, we chat with Evan Appleton, chief scientific officer and co-founder of Intertwined, a company focused on understanding mammalian evolved protective traits, and how they can be transferred to humans. And we chat with Lew Bender, CEO of Intensity Therapeutics, which is pioneering an intratumoral injection therapy primarily for breast cancer that not only kills the cancer cells in the tumour but throughout the body as well, acting as almost a cancer-killing vaccine. Times: 04:22 Intertwined 29:06 Intensity Therapeutics Intensity Therapeutics Intensity is a late-stage clinical biotech company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumour's dense, high-fat, pressurised environment following direct intratumoral injection. Its clinical trials have demonstrated the ability of INT230-6 to kill tumours and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases, even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies: a phase 1/2 dose-escalation study in metastatic cancers including sarcomas, and a phase 2 randomised controlled clinical trial in locally advanced breast cancer in women without undergoing chemotherapy prior to their surgery. Intertwined Evolution has led to species developing in different ways. Hundreds of millions of years of evolution have produced animals that resist diseases humans still struggle to treat. The mechanisms are already there - in their cells, in their DNA. Intertwined Biosciences is using those “blueprints” to decode disease-resistance mechanisms from the world’s most resilient animals and engineer them into human immune cells - powered by the company’s Virtual Immune Cell model. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 77: Transferring mammal traits to humans, and is injecting tumours a new way to kill cancer?

  7. Sep 18

    Base to Base biotech podcast 76: Early disease detection and beating CNS cancers

    This week, we have conversations with Marc Hedrick, CEO of Cerenome, about a combined approach to tackling central nervous system (CNS) cancers, and Shaun Holt, CEO of Alveo Technologies, about the potential for animal diseases to jump to humans, and what we can do about it. Times: 03:27 Cerenome 28:27 Alveo Technologies Cerenome Cerenome, formerly known as Plus Therapeutics, is a central nervous system (CNS) oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The company’s CNSide Diagnostics platform supports the detection, molecular characterisation, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and paediatric brain cancers. The data and artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. Alveo Technologies Alveo Technologies, Inc. is a global molecular diagnostics company working on rapid, point-of-need molecular diagnostics for early disease detection. It has developed a portable, cloud-connected platform that brings laboratory-quality pathogen detection directly to the Point of Need for farmers, veterinarians and public health officials. By decentralising molecular diagnostics, Alveo enables rapid detection and decision-making to help protect animal and human health, food security and supply chain resiliency. The company recently announced a strategic partnership with AgriNerds Inc, which has developed the Waterfowl Alert Network, a first-of-its-kind dynamic surveillance and awareness programme that predicts historic and daily waterfowl activity around the nation's poultry and livestock farms. The partnership will pair Alveo's molecular diagnostic with AgriNerds' Waterfowl Alert Network, a proprietary system that uses a combination of satellite imagery, weather radar, and telemetry to create daily farm-level HPAI risk scores based on remote sensing and HPAI surveillance data. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 76: Early disease detection and beating CNS cancers

  8. Sep 11

    Base to Base biotech podcast 75: AI-powered diagnostics and cancer immunotherapy

    Times: 03:17 Asgard Therapeutics 32:43 Waiv This week, we talk to a company in Lund, Asgard Therapeutics, and its co-founder and CEO Cristiana Pires, about in vivo direct cell reprogramming for cancer immunotherapy, and we chat about clinical diagnostics with Meriem Sefta, CEO of Waiv. Asgard Therapeutics Asgard Therapeutics is a biotech pioneering in vivo direct cell reprogramming for cancer immunotherapy. Asgard is using an innovative approach to force tumour cells to present their antigens to the immune system, thereby triggering personalised anti-tumour immune responses. The team presented advanced preclinical data on lead asset AT-108 at ASGCT earlier this year, showing that, when used as a monotherapy, AT-108 doubled median survival. When used in combination with immune checkpoint blockade, AT-108 demonstrated strong anti-tumour activity, including significantly extending survival and achieving complete tumour regressions. AI-powered diagnostics Waiv is a precision oncology company that spun out of Owkin last year to focus exclusively on AI-powered diagnostics. Waiv uses its AI to analyse routine pathology images, helping clinicians identify patients who may benefit from further molecular testing and ultimately the right treatment, without requiring additional tissue needed by requesting additional painful patient biopsies or changes to clinical workflow. Its tests accelerate biomarker discovery and detection, outcome prediction, and treatment-response assessment across oncology. Built on over seven years of validated medical-AI innovation and one of Europe’s largest multi-institutional data networks, Waiv delivers precise, accurate, and fast analyses that support treatment decisions. It collaborates with global pharmaceutical companies, research institutions, diagnostic organisations and healthcare systems to bring scalable precision medicine to patients worldwide. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 75: AI-powered diagnostics and cancer immunotherapy
See All (82)

About

The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.

Information

  • Creator
    Jim Cornall
  • Years Active
    2025 - 2026
  • Episodes
    82
  • Rating
    Clean
  • Copyright
    © Ayr Coastal Media Ltd 2025
  • Show Website
    Base to Base Biotech

You Might Also Like